KRYS on XNAS, Health Care, Krystal Biotech, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue rose 26% to $470M while insiders sold $18M and 10% of shares are sold short.
GoodNet income rose 13% to $225.2M over the last 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $127.3M, net income $63.1M.
31 Dec 2021RevenueNet incomeNet losstallest bar $127.3M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$127.3M
$63.1M
30 Jun 2026
$119.2M
$54.8M
31 Mar 2026
$116.4M
$55.9M
31 Dec 2025
$107.1M
$51.4M
30 Sep 2025
$97.8M
$79.4M
30 Jun 2025
$96.0M
$38.3M
31 Mar 2025
$88.2M
$35.7M
31 Dec 2024
$91.1M
$45.5M
30 Sep 2024
$83.8M
$27.2M
30 Jun 2024
$70.3M
$15.6M
31 Mar 2024
$45.2M
$932K
31 Dec 2023
$42.1M
$8.7M
30 Sep 2023
$8.6M
$80.7M
30 Jun 2023
$0
-$33.2M
31 Mar 2023
$0
-$45.3M
31 Dec 2022
$0
-$32.1M
30 Sep 2022
$0
-$29.9M
30 Jun 2022
–
-$28.1M
31 Mar 2022
–
-$50.0M
31 Dec 2021
–
-$21.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$470.0M
$373.2M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+26%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$225.2M
$198.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$7.37
$6.68
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
48.4%
42.4%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
47.9%
53.3%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
17.5%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$310.1M
$165.6M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$911.9M
$731.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$911.9M (net cash)
-$731.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$48.44
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
40.7
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
19.5
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
17.5
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
6.4
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$18.0M
bought $0, sold $18.0M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+5.5%
440 13F filers vs 417
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
98%
29.0M shares held by 13F filers (30 Sep 2026) of 29.6M outstanding (28 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
10%
3.0M shares sold short (30 Oct 2026) of 29.6M outstanding (28 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
12.2
3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+3.7%
2.9M shares sold short in the report before, 3.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
83%
83% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 75%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+30%
$127.3M vs $97.8M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-42%
$996K vs $1.7M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
25
25 articles in the last 7 days; its usual week has 4.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.6×
25 articles in the last 7 days; its usual week has 4.5.
Price $308.89 on 20 Nov 2026, +51% over 12 months (12-month range $204.22 to $378.15)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $105.3M in the last 12 months (the 12 months before: -$49.4M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $127.3M in the latest quarter, +30% on a year earlier.Capital spending per quarter. Capital spending $996K in the latest quarter, -42% on a year earlier.Institutional holders (13F filers). 440 13F filers reported holding it in the latest 13F quarter, +61% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 30 Sep 2022: $0; public on 7 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 27 Feb 2024
Quarter ended 31 Mar 2023: $0; public on 7 May 2024
Quarter ended 30 Jun 2023: $0; public on 6 Aug 2024
Quarter ended 30 Sep 2023: $8.6M; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $42.1M; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $45.2M; public on 7 May 2024
Quarter ended 30 Jun 2024: $70.3M; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $83.8M, +880% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $91.1M, +116% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $88.2M, +95% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $96.0M, +37% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $97.8M, +17% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $107.1M, +18% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $116.4M, +32% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $119.2M, +24% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $127.3M, +30% on a year earlier; public on 3 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $17.2M, +595% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $16.5M, +314% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $14.1M, -33% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $5.2M; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $5.4M, -69% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $2.8M, -83% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $1.8M, -87% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $1.8M, -65% on a year earlier; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $1.3M, -77% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $1.1M, -59% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $1.0M, -41% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $801K, -57% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $6.2M, +392% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.9M, +68% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $1.7M, +63% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $2.1M, +167% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $7.1M, +15% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $3.6M, +87% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $996K, -42% on a year earlier; public on 3 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 132; public on 14 Feb 2022
31 Mar 2022 report: 127; public on 16 May 2022
30 Jun 2022 report: 130; public on 15 Aug 2022
30 Sep 2022 report: 138; public on 14 Nov 2022
31 Dec 2022 report: 148; public on 14 Feb 2023
31 Mar 2023 report: 152; public on 15 May 2023
30 Jun 2023 report: 172; public on 14 Aug 2023
30 Sep 2023 report: 175; public on 14 Nov 2023
31 Dec 2023 report: 186; public on 14 Feb 2024
31 Mar 2024 report: 220; public on 15 May 2024
30 Jun 2024 report: 231; public on 14 Aug 2024
30 Sep 2024 report: 267; public on 14 Nov 2024
31 Dec 2024 report: 255; public on 14 Feb 2025
31 Mar 2025 report: 285; public on 15 May 2025
30 Jun 2025 report: 261; public on 14 Aug 2025
30 Sep 2025 report: 274; public on 14 Nov 2025
31 Dec 2025 report: 322; public on 17 Feb 2026
31 Mar 2026 report: 356; public on 15 May 2026
30 Jun 2026 report: 417; public on 14 Aug 2026
30 Sep 2026 report: 440; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 440 (30 Sep 2026), 1.7× its normal reading; higher than 100% of its own history.
Two or more unrelated kinds of records unusual within 30 days
19 Nov 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Krystal Biotech(KRYS): reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year, while it saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year. Two unrelated kinds of activity within 14 days.
Financials: Quarterly revenue change, became public on 5 Nov 2024
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
The quarter ended 30 Sep 2024 against the 8 quarters before it.
this quarterearliernormal: $4.3MSee the evidence (2 changes)
Financials: Quarterly revenue change became public on 5 Nov 2024
Krystal Biotech reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year.
This period
$83.8M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$4.3M
Typical spread (median absolute deviation)
$4.3M
How far from its usual level
+12.5
Same quarter last year
$8.6M
History used
731 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $4.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
Krystal Biotech saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year.
This period
50 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
20.5
Typical spread (median absolute deviation)
5.5
How far from its usual level
+3.6
Same quarter last year
15
History used
2,557 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
20 Aug 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
Krystal Biotech(KRYS): reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year; it also saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year; and it had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year. Three unrelated kinds of activity within 42 days.
Financials: Quarterly revenue change, became public on 6 Aug 2024
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
Short interest and volume: Short interest spike, became public on 12 Sep 2024
The quarter ended 30 Jun 2024 against the 7 quarters before it.
this quarterearliernormal: $0See the evidence (3 changes)
Financials: Quarterly revenue change became public on 6 Aug 2024
Krystal Biotech reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year.
This period
$70.3M (the quarter ended 30 Jun 2024)
Normal quarter (median of 7 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+70.3
Same quarter last year
$0
History used
639 days
the quarter ended 30 Jun 20247 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2024
Krystal Biotech saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year.
This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
18
Typical spread (median absolute deviation)
3
How far from its usual level
+5.8
Same quarter last year
36
History used
2,465 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 18
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Krystal Biotech had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year.
This period
3.7M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
261K
How far from its usual level
+3.9
Same report last year
1.5M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Nov 2021confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Krystal Biotech(KRYS): spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year, while it had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year. Two unrelated kinds of activity within 35 days.
Financials: Quarterly capital spending jump, became public on 9 Nov 2021
Short interest and volume: Short interest spike, became public on 10 Nov 2021
Short interest and volume: Short interest spike, became public on 25 Nov 2021
Short interest and volume: Short interest spike, became public on 10 Dec 2021
The quarter ended 30 Sep 2021 against the 8 quarters before it.
this quarterearliernormal: $2.4MSee the evidence (4 changes)
Financials: Quarterly capital spending jump became public on 9 Nov 2021
Krystal Biotech spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year.
This period
$21.0M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$2.4M
Typical spread (median absolute deviation)
$1.0M
How far from its usual level
+12.1
Same quarter last year
$4.2M
History used
1,734 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $2.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 Nov 2021
Krystal Biotech had 1.8M shares sold short in the 29 Oct 2021 report, 1.2× the same report last year.
This period
1.8M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+3.6
Same report last year
1.5M
History used
1,400 days
the 29 Oct 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Nov 2021
Krystal Biotech had 2.1M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.
This period
2.1M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+5.1
Same report last year
1.4M
History used
1,417 days
the 15 Nov 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2021
Krystal Biotech had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year.
This period
2.2M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+6.0
Same report last year
1.4M
History used
1,432 days
the 30 Nov 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
23 Dec 2025Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
spent $6.2M on capital projects in the quarter ended 31 Mar 2025, 4.9× the same quarter last year.
Same quarter last year: $1.3M; its normal quarter is $1.5M.
See the evidence
This period
$6.2M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$1.5M
Typical spread (median absolute deviation)
$432K
How far from its usual level
+4.7
Same quarter last year
$1.3M
History used
3,012 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $1.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year, while it saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year. Two unrelated kinds of activity within 14 days.
See the evidence (2 changes)
Financials: Quarterly revenue change became public on 5 Nov 2024
Krystal Biotech reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year.
This period
$83.8M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$4.3M
Typical spread (median absolute deviation)
$4.3M
How far from its usual level
+12.5
Same quarter last year
$8.6M
History used
731 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $4.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
Krystal Biotech saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year.
This period
50 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
20.5
Typical spread (median absolute deviation)
5.5
How far from its usual level
+3.6
Same quarter last year
15
History used
2,557 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2024Institutional holdings change
saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year.
Same quarter last year: 15; its normal quarter is 20.5.
See the evidence
This period
50 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
20.5
Typical spread (median absolute deviation)
5.5
How far from its usual level
+3.6
Same quarter last year
15
History used
2,557 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year.
Same quarter last year: $8.6M; its normal quarter is $4.3M.
See the evidence
This period
$83.8M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$4.3M
Typical spread (median absolute deviation)
$4.3M
How far from its usual level
+12.5
Same quarter last year
$8.6M
History used
731 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $4.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year.
Same report last year: 1.5M; its normal report is 2.2M.
See the evidence
This period
3.7M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
261K
How far from its usual level
+3.9
Same report last year
1.5M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year; it also saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year; and it had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year. Three unrelated kinds of activity within 42 days.
See the evidence (3 changes)
Financials: Quarterly revenue change became public on 6 Aug 2024
Krystal Biotech reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year.
This period
$70.3M (the quarter ended 30 Jun 2024)
Normal quarter (median of 7 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+70.3
Same quarter last year
$0
History used
639 days
the quarter ended 30 Jun 20247 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2024
Krystal Biotech saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year.
This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
18
Typical spread (median absolute deviation)
3
How far from its usual level
+5.8
Same quarter last year
36
History used
2,465 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 18
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Krystal Biotech had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year.
This period
3.7M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
261K
How far from its usual level
+3.9
Same report last year
1.5M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Aug 2024Institutional holdings change
saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year.
Same quarter last year: 36; its normal quarter is 18.
See the evidence
This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
18
Typical spread (median absolute deviation)
3
How far from its usual level
+5.8
Same quarter last year
36
History used
2,465 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 18
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year.
See the evidence
This period
$70.3M (the quarter ended 30 Jun 2024)
Normal quarter (median of 7 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+70.3
Same quarter last year
$0
History used
639 days
the quarter ended 30 Jun 20247 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 57 13F filers open a new position in the quarter ended 31 Mar 2024, 3.8× the same quarter last year.
Same quarter last year: 15; its normal quarter is 17.5.
See the evidence
This period
57 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
17.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+10.7
Same quarter last year
15
History used
2,374 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 2.1M shares sold short in the 30 Nov 2023 report, 1.8× the same report last year.
Same report last year: 1.2M; its normal report is 1.2M.
See the evidence
This period
2.1M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
113K
How far from its usual level
+5.3
Same report last year
1.2M
History used
2,162 days
the 30 Nov 2023 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 15 Nov 2023 report, 1.7× the same report last year.
Same report last year: 1.2M; its normal report is 1.2M.
See the evidence
This period
2.1M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
103K
How far from its usual level
+5.5
Same report last year
1.2M
History used
2,147 days
the 15 Nov 2023 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 31 Oct 2023 report, 1.6× the same report last year.
Same report last year: 1.3M; its normal report is 1.2M.
See the evidence
This period
2.1M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
99K
How far from its usual level
+6.0
Same report last year
1.3M
History used
2,132 days
the 31 Oct 2023 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 13 Oct 2023 report, 1.5× the same report last year.
Same report last year: 1.3M; its normal report is 1.2M.
See the evidence
This period
2.0M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
90K
How far from its usual level
+5.5
Same report last year
1.3M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 29 Sep 2023 report, 1.5× the same report last year.
Same report last year: 1.3M; its normal report is 1.2M.
See the evidence
This period
2.0M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
85K
How far from its usual level
+5.9
Same report last year
1.3M
History used
2,100 days
the 29 Sep 2023 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 36 13F filers open a new position in the quarter ended 30 Jun 2023, 2.0× the same quarter last year.
Same quarter last year: 18; its normal quarter is 16.
See the evidence
This period
36 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
16
Typical spread (median absolute deviation)
2
How far from its usual level
+6.7
Same quarter last year
18
History used
2,099 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 16
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
spent $16.5M on capital projects in the quarter ended 30 Jun 2022, 4.1× the same quarter last year.
Same quarter last year: $4.0M; its normal quarter is $4.1M.
See the evidence
This period
$16.5M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$4.1M
Typical spread (median absolute deviation)
$2.4M
How far from its usual level
+3.6
Same quarter last year
$4.0M
History used
2,007 days
the quarter ended 30 Jun 20228 earlier quartersnormal: $4.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $17.2M on capital projects in the quarter ended 31 Mar 2022, 7.0× the same quarter last year.
Same quarter last year: $2.5M; its normal quarter is $3.2M.
See the evidence
This period
$17.2M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$3.2M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+8.4
Same quarter last year
$2.5M
History used
1,916 days
the quarter ended 31 Mar 20228 earlier quartersnormal: $3.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 33 13F filers open a new position in the quarter ended 31 Dec 2021, 2.1× the same quarter last year.
Same quarter last year: 16; its normal quarter is 12.
See the evidence
This period
33 (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
12
Typical spread (median absolute deviation)
2
How far from its usual level
+7.0
Same quarter last year
16
History used
1,553 days
the quarter ended 31 Dec 20218 earlier quartersnormal: 12
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year.
Same report last year: 1.4M; its normal report is 1.3M.
See the evidence
This period
2.2M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+6.0
Same report last year
1.4M
History used
1,432 days
the 30 Nov 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.
Same report last year: 1.4M; its normal report is 1.3M.
See the evidence
This period
2.1M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+5.1
Same report last year
1.4M
History used
1,417 days
the 15 Nov 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year, while it had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year. Two unrelated kinds of activity within 35 days.
See the evidence (4 changes)
Financials: Quarterly capital spending jump became public on 9 Nov 2021
Krystal Biotech spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year.
This period
$21.0M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$2.4M
Typical spread (median absolute deviation)
$1.0M
How far from its usual level
+12.1
Same quarter last year
$4.2M
History used
1,734 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $2.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 Nov 2021
Krystal Biotech had 1.8M shares sold short in the 29 Oct 2021 report, 1.2× the same report last year.
This period
1.8M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+3.6
Same report last year
1.5M
History used
1,400 days
the 29 Oct 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Nov 2021
Krystal Biotech had 2.1M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.
This period
2.1M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+5.1
Same report last year
1.4M
History used
1,417 days
the 15 Nov 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2021
Krystal Biotech had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year.
This period
2.2M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+6.0
Same report last year
1.4M
History used
1,432 days
the 30 Nov 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
10 Nov 2021Short interest and volume change
had 1.8M shares sold short in the 29 Oct 2021 report, 1.2× the same report last year.
Same report last year: 1.5M; its normal report is 1.3M.
See the evidence
This period
1.8M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+3.6
Same report last year
1.5M
History used
1,400 days
the 29 Oct 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year.
Same quarter last year: $4.2M; its normal quarter is $2.4M.
See the evidence
This period
$21.0M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$2.4M
Typical spread (median absolute deviation)
$1.0M
How far from its usual level
+12.1
Same quarter last year
$4.2M
History used
1,734 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $2.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $7.2M on capital projects in the quarter ended 31 Dec 2020, 3.2× the same quarter last year.
Same quarter last year: $2.3M; its normal quarter is $1.6M.
See the evidence
This period
$7.2M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$1.6M
Typical spread (median absolute deviation)
$354K
How far from its usual level
+5.6
Same quarter last year
$2.3M
History used
1,461 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $1.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 2.0M shares sold short in the 15 Nov 2019 report, 12× the same report last year.
Same report last year: 174K; its normal report is 580K.
See the evidence
This period
2.0M (the 15 Nov 2019 report)
Normal report (median of 24 earlier)
580K
Typical spread (median absolute deviation)
269K
How far from its usual level
+3.7
Same report last year
174K
History used
686 days
the 15 Nov 2019 report24 earlier reportsnormal: 580K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 59 entries; narrow the window or the kind of data to see older ones.
Not listed: 170 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001711279
Ticker
KRYS
Domain
krystalbio.com
Employer name
KRYSTAL BIOTECH, INC. (1 unverified)
Hq location
PA|PITTSBURGH|15203 (1 unverified)
Name
a4q25krysex211.htm, Document, EX-21.1, Krystal Biotech, Inc.
Uei
H5VRRQJHRBL3
Wikidata
Q124665205
DOL H-1B labor condition applications and PERM certifications32 data points16 Mar 2020 to 23 Feb 2026
SEC Form 13F institutional holdings333 data points30 Sep 2017 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)109 records18 Aug 2017 to 2 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)610 data points30 Sep 2016 to 28 Oct 2026
SEC Form 4 insider transactions85 records, 216 data points25 Sep 2017 to 4 Sep 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026